These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 9176498)
1. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Melero I; Shuford WW; Newby SA; Aruffo A; Ledbetter JA; Hellström KE; Mittler RS; Chen L Nat Med; 1997 Jun; 3(6):682-5. PubMed ID: 9176498 [TBL] [Abstract][Full Text] [Related]
2. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice. Sabel MS; Conway TF; Chen FA; Bankert RB J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665 [TBL] [Abstract][Full Text] [Related]
4. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Melero I; Bach N; Hellström KE; Aruffo A; Mittler RS; Chen L Eur J Immunol; 1998 Mar; 28(3):1116-21. PubMed ID: 9541607 [TBL] [Abstract][Full Text] [Related]
5. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. Wen T; Bukczynski J; Watts TH J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439 [TBL] [Abstract][Full Text] [Related]
6. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270 [TBL] [Abstract][Full Text] [Related]
7. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. May KF; Chen L; Zheng P; Liu Y Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989 [TBL] [Abstract][Full Text] [Related]
8. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. Shuford WW; Klussman K; Tritchler DD; Loo DT; Chalupny J; Siadak AW; Brown TJ; Emswiler J; Raecho H; Larsen CP; Pearson TC; Ledbetter JA; Aruffo A; Mittler RS J Exp Med; 1997 Jul; 186(1):47-55. PubMed ID: 9206996 [TBL] [Abstract][Full Text] [Related]
9. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763 [TBL] [Abstract][Full Text] [Related]
10. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. Bertram EM; Dawicki W; Sedgmen B; Bramson JL; Lynch DH; Watts TH J Immunol; 2004 Jan; 172(2):981-8. PubMed ID: 14707071 [TBL] [Abstract][Full Text] [Related]
11. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. Sun Y; Lin X; Chen HM; Wu Q; Subudhi SK; Chen L; Fu YX J Immunol; 2002 Feb; 168(3):1457-65. PubMed ID: 11801689 [TBL] [Abstract][Full Text] [Related]
12. Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes. Nam KO; Kang H; Shin SM; Cho KH; Kwon B; Kwon BS; Kim SJ; Lee HW J Immunol; 2005 Feb; 174(4):1898-905. PubMed ID: 15699116 [TBL] [Abstract][Full Text] [Related]
13. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282 [TBL] [Abstract][Full Text] [Related]
14. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570 [TBL] [Abstract][Full Text] [Related]
16. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Futagawa T; Akiba H; Kodama T; Takeda K; Hosoda Y; Yagita H; Okumura K Int Immunol; 2002 Mar; 14(3):275-86. PubMed ID: 11867564 [TBL] [Abstract][Full Text] [Related]
17. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348 [TBL] [Abstract][Full Text] [Related]
18. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726 [TBL] [Abstract][Full Text] [Related]
19. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Ju SA; Lee SC; Kwon TH; Heo SK; Park SM; Paek HN; Suh JH; Cho HR; Kwon B; Kwon BS; Kim BS Immunol Cell Biol; 2005 Aug; 83(4):344-51. PubMed ID: 16033529 [TBL] [Abstract][Full Text] [Related]
20. Cooperation between 4-1BB and ICOS in the immune response to influenza virus revealed by studies of CD28/ICOS-deficient mice. Vidric M; Suh WK; Dianzani U; Mak TW; Watts TH J Immunol; 2005 Dec; 175(11):7288-96. PubMed ID: 16301634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]